A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas.

Trial Profile

A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 08 Jul 2015

At a glance

  • Drugs Belinostat (Primary)
  • Indications Cutaneous T cell lymphoma; Peripheral T-cell lymphoma
  • Focus Therapeutic Use
  • Sponsors TopoTarget
  • Most Recent Events

    • 26 Oct 2014 Status changed from completed to discontinued as study had accumulated sufficient data to allow a registration study in PTCL (PXD101-CLN-19), as reported by CliniclTrials.gov .
    • 01 Sep 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 22 Dec 2009 Additional locations [France, Germany, Israel, Thailand] added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top